GlassScriptPhysician profile
Monica Griffith
NPI 1215601349
$12,515.98
in general payments reported to CMS, 2019-2025
25 companies · $4,023 in 2025
The $4,023 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $156 · 2022: $2,167 · 2023: $2,953 · 2024: $3,218 · 2025: $4,023.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,077.72 |
| Education | $115.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $2,042.54 | 2021-2025 | Ingrezza |
| Abbvie INC. | $1,600.16 | 2022-2025 | |
| Axsome Therapeutics, INC. | $1,230.00 | 2023-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $1,214.23 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,059.00 | 2021-2025 | Caplyta |
| Alkermes, INC. | $1,013.58 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Teva Pharmaceuticals USA, INC. | $917.03 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Janssen Pharmaceuticals, INC | $798.08 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Lundbeck LLC | $655.39 | 2022-2025 | Rexulti, Abilify Maintena, Brintellix |
| Takeda Pharmaceuticals U.S.A., INC. | $501.15 | 2022-2025 | Trintellix |
| Corium, LLC | $407.55 | 2022-2025 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $191.33 | 2024-2025 | Cobenfy |
| Indivior INC. | $141.54 | 2022-2025 | Sublocade, Perseris |
| Sunovion Pharmaceuticals INC. | $127.66 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $110.78 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $106.03 | 2024-2025 | Fanapt, Hetlioz |
| Ironshore Pharmaceuticals INC. | $89.97 | 2022-2024 | Jornay Pm |
| Noven Therapeutics, LLC | $71.85 | 2025 | Xelstrym, Secuado |
| Supernus Pharmaceuticals, INC. | $66.36 | 2025 | Qelbree |
| Sage Therapeutics, LLC | $48.68 | 2025 | Zurzuvae |
| Hikma Pharmaceuticals USA | $36.94 | 2024 | Kloxxado |
| Bausch Health US, LLC | $34.36 | 2022 | |
| Tris Pharma INC | $18.00 | 2023 | Dyanavel Xr |
| Collegium Pharmaceutical, INC. | $17.49 | 2025 | Jornay Pm |
| Acadia Pharmaceuticals INC | $16.28 | 2023 | Nuplazid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monica Griffith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.